Virtu Financial LLC Buys New Stake in IDEXX Laboratories, Inc. $IDXX

Virtu Financial LLC purchased a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the 4th quarter, Holdings Channel.com reports. The firm purchased 3,584 shares of the company’s stock, valued at approximately $2,424,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Virtus Advisers LLC acquired a new position in IDEXX Laboratories in the third quarter valued at $26,000. Park Place Capital Corp acquired a new stake in shares of IDEXX Laboratories during the fourth quarter worth about $29,000. WealthCollab LLC acquired a new stake in shares of IDEXX Laboratories during the second quarter worth about $30,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of IDEXX Laboratories in the 3rd quarter valued at about $36,000. Finally, Mowery & Schoenfeld Wealth Management LLC lifted its holdings in shares of IDEXX Laboratories by 58.8% in the 4th quarter. Mowery & Schoenfeld Wealth Management LLC now owns 54 shares of the company’s stock valued at $37,000 after purchasing an additional 20 shares during the last quarter. 87.84% of the stock is owned by hedge funds and other institutional investors.

IDEXX Laboratories Price Performance

Shares of NASDAQ:IDXX opened at $562.09 on Friday. The company has a 50-day simple moving average of $561.66 and a 200-day simple moving average of $620.91. IDEXX Laboratories, Inc. has a one year low of $506.91 and a one year high of $769.98. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.82 and a current ratio of 1.12. The stock has a market capitalization of $44.34 billion, a price-to-earnings ratio of 41.39, a PEG ratio of 3.07 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, topping the consensus estimate of $3.41 by $0.06. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The business had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.12 billion. During the same quarter in the prior year, the firm earned $2.91 earnings per share. The business’s quarterly revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, analysts predict that IDEXX Laboratories, Inc. will post 14.68 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on IDXX shares. Stifel Nicolaus decreased their target price on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research report on Tuesday, March 31st. Citigroup began coverage on IDEXX Laboratories in a research report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price target on the stock. UBS Group reduced their price objective on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research note on Tuesday, April 28th. Weiss Ratings downgraded IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, May 11th. Finally, Wall Street Zen upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Saturday, June 13th. Seven analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, IDEXX Laboratories has a consensus rating of “Moderate Buy” and a consensus target price of $751.00.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.